Item 7.01 Regulation FD Disclosure
On January 26, 2023, Monopar Therapeutics Inc. issued a press release announcing
it is planning to report over the next two months (1) the interim go/no-go
analysis for its Validive Phase 2b/3 VOICE trial, (2) clinical data from its
camsirubicin Phase 1b trial, and (3) a preclinical progress update on its
MNPR-101 RIT program.
The press release is furnished as Exhibit 99.1 to this report and incorporated
herein by reference
Item 9.01 Financial Statements and Exhibits
Exhibit No. Description
99.1 Press Release Dated January 26, 2023
2
© Edgar Online, source Glimpses